Kato H - Search Results

1

Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF.

Okamoto A, Asai T, Kato H, Ando H, Minamino T, Mekada E, Oku N. Okamoto A, et al. Among authors: kato h. Biochem Biophys Res Commun. 2014 Jul 11;449(4):460-5. doi: 10.1016/j.bbrc.2014.05.043. Epub 2014 May 20. Biochem Biophys Res Commun. 2014. PMID: 24853808

2

Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector.

Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N, Oku N. Koide H, et al. Among authors: kato h. Biol Pharm Bull. 2011;34(5):602-8. doi: 10.1248/bpb.34.602. Biol Pharm Bull. 2011. PMID: 21532145 Free article.

3

Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles.

Koide H, Asai T, Kato H, Ando H, Shiraishi K, Yokoyama M, Oku N. Koide H, et al. Among authors: kato h. Int J Pharm. 2012 Aug 1;432(1-2):75-9. doi: 10.1016/j.ijpharm.2012.04.049. Epub 2012 Apr 26. Int J Pharm. 2012. PMID: 22562054

4

Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin.

Koide H, Asai T, Kato H, Yonenaga N, Yokota M, Ando H, Dewa T, Nango M, Maeda N, Oku N. Koide H, et al. Among authors: kato h. Nanomedicine. 2015 Jan;11(1):185-94. doi: 10.1016/j.nano.2014.09.003. Epub 2014 Sep 18. Nanomedicine. 2015. PMID: 25240598

5

CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.

Kato H, Seto K, Kobayashi N, Yoshinaga K, Meyer T, Takei M. Kato H, et al. Life Sci. 2011 Oct 24;89(17-18):603-8. doi: 10.1016/j.lfs.2011.07.019. Epub 2011 Aug 3. Life Sci. 2011. PMID: 21839751

6

New natural products isolated from Metarhizium robertsii ARSEF 23 by chemical screening and identification of the gene cluster through engineered biosynthesis in Aspergillus nidulans A1145.

Kato H, Tsunematsu Y, Yamamoto T, Namiki T, Kishimoto S, Noguchi H, Watanabe K. Kato H, et al. J Antibiot (Tokyo). 2016 Jul;69(7):561-6. doi: 10.1038/ja.2016.54. Epub 2016 May 18. J Antibiot (Tokyo). 2016. PMID: 27189118

7

Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.

Minami T, Takeda M, Sata M, Kato H, Yano K, Sakai T, Tsujita R, Kawasaki K, Ito A. Minami T, et al. Among authors: kato h. Eur J Pharmacol. 2020 Aug 5;880:173196. doi: 10.1016/j.ejphar.2020.173196. Epub 2020 May 13. Eur J Pharmacol. 2020. PMID: 32416186 Free article.

8

Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.

Orikawa Y, Kato H, Seto K, Kobayashi N, Yoshinaga K, Hamano H, Hori Y, Meyer T, Takei M. Orikawa Y, et al. Among authors: kato h. Mol Pain. 2010 Oct 28;6:72. doi: 10.1186/1744-8069-6-72. Mol Pain. 2010. PMID: 20979661 Free PMC article.

9

Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2 g once daily in a murine model of Streptococcus pneumoniae pneumonia.

Kato H, Hagihara M, Hiramatsu SI, Suematsu H, Nishiyama N, Asai N, Mikamo H, Yamamoto K, Iwamoto T. Kato H, et al. JAC Antimicrob Resist. 2024 Jun 4;6(3):dlae092. doi: 10.1093/jacamr/dlae092. eCollection 2024 Jun. JAC Antimicrob Resist. 2024. PMID: 38836196 Free PMC article.

10

Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial.

Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y. Fujimura T, et al. Among authors: kato h. Br J Dermatol. 2024 Jun 4:ljae231. doi: 10.1093/bjd/ljae231. Online ahead of print. Br J Dermatol. 2024. PMID: 38833158

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,010 results

Search Page